Supernus Announces Fourth Quarter and Full Year 2014 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Supernus Pharmaceuticals (SUPN) PT Raised to $16 at Piper Jaffray Post Q4
March 12, 2015 7:21 AM EDTPiper Jaffray analyst David Amsellem reiterated an Overweight rating and boosted his price target on Supernus Pharmaceuticals (NASDAQ: SUPN) to $16.00 (from $14.00) following Q4 results, noting continued strength for the epilepsy franchise.
Amsellem commented, "Supernus reported non-GAAP EPS of $0.08 on revenues of $31M, well... More
Supernus Pharma (SUPN) Tops Q4 EPS by 3c
March 10, 2015 5:01 PM EDTSupernus Pharma (NASDAQ: SUPN) reported Q4 EPS of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $30.8 million versus the consensus estimate of $24.4 million.
For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.
... More